HIV Testing and Systems for Managing HIV Implementation in Resource Limited Settings

Similar documents
Donor Screening in The Region. Vincini GA NRL, Melbourne, Australia

NRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2017Oct27

HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2017Apr19

The use of QCMD proficiency testing panels in clinical virology.

Mom Chandara, Msc, NIPH Team

BLOOD SAFETY STATUS IN INDONESIA. Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine

HIV Serology Quality Assessment Program Revised Summary for Panel HIVSER 2017Oct27

Il ruolo delle VEQ per la sicurezza trasfusionale

HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2016Oct28

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2018Apr19

FINAL REPORT HBV Serology External Quality Assessment Scheme

Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013

WHO Prequalification of In Vitro Diagnostics Programme

NAT Screening of Blood Donations in NBC, TRCS

Update on WHO Prequalification of In Vitro Diagnostics

FINAL REPORT HBV Serology External Quality Assessment Scheme

HTLV Serology Quality Assessment Program Summary for Panel HTLS Oct22

Vision and strategies to Increase Access to Innovative HIV Diagnostic Technologies. Willy Urassa. AMD STAKE HOLDERS MEETING 7-8 May 2013

External Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience

INTERPRETING HEPATITIS B SEROLOGY

Understanding Quality Control for Infectious Disease Testing. Wayne Dimech ASLM Quality Control Workshop Abuja, Nigeria 9 th December 2018

Evolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention

The Laboratories Role in Global Health

VIDRL & WHO Measles IgM Proficiency Panel Final Report Prepared by Jennie Leydon, Michaela Riddell & Dr Mike Catton Director VIDRL

True Status A B. HTLV I Positive. Indeterminate. HTLV I/II Negative HV15 HV16 HV18 HV21 HV22 HV44 HV55. Selected Legend: Flagged: Unresolved

Point of Care Testing for INR using CoaguChek XS Plus

Structure and duties of Blood service

to be notified: all parties involved in the graduated plan procedure. Annexes

Achieving the first 90 and doing it right

QA Processes. Philip DaCosta BSCP QA Lead, Yorkshire & the Humber September 2013

Fifteen years of molecular EQA: progress and challenges

Introduction to Quality Management Systems

ANNEX 8: Ensuring the quality of HIV testing services

2015/LSIF/FOR/009 Securing Political and Financial Support for Blood Safety - Philippine Experience

For information only: all participants in the graduated plan procedure. 7 January 2013

Impact of multi-dye multiplex technology on testing algorithm

Workshop on Proficiency Testing for Medical Laboratories. Daniel W. Tholen, M.S. March 13, 2013

Point of care, near patient testing, of blood borne viruses issues with design and implementation of programs

Acylcarnitine Analysis using the Perkin Elmer Neobase Kit. Katherine Wright Alder Hey, Liverpool

Annex 13. Indicators for HIV testing services reference sheet

WHO Guidelines on hepatitis B and C testing

Quality Corner: Inspection Preparation By Rhonda Burgard, Client Services Supervisor

AccuVert HIV-1 Seroconversion Panel PRB955 ( ) / Batch #

The Alphabet Soup of Viral Hepatitis Testing

Confirmatory Testing Algorithm. Routine Donor Testing Algorithm

Viral Hepatitis Surveillance in Tennessee

INTERNAL QUALITY CONTROL ( Q I C) QC)

Accreditation in the Philippines

Implementation of High Risk Human Papilloma Virus (Hr-HPV) Primary Testing

VARIATION IN MEASUREMENT OF HIV RNA VIRAL LOAD

Key Considerations in Implementing HIV Point-of-Care testing in Kenya

NATIONAL STANDARD METHODS: ASSURING QUALITY IN UK Portugal

Official Journal of the European Communities COMMISSION

Khalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia

Bioanalytical Issues when. Brigitte Pellerin Bioanalytical Associate Director

RECALL / EVENT INVESTIGATION & PATIENT LOOK BACK

HIV Serology Quality Assessment Program Summary for Panel HIVS Oct22

PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA

2006 HIV Diagnostics Survey

QSEAL Recovered Plasma Specification

AccuSet HCV Performance Panel

HIV-1 AccuVert Seroconversion Panel (PRB966) / Batch #

Multichem Infectious Disease QC

Trends in molecular diagnostics

How best to structure a laboratory network with new technologies

for Microbiology Quality Assessment Programmes for HPV and MRSA Effect of change to assessment categories for HBV DNA Dr Vivienne James SoGAT 2009

Microscopy Studies. Evaluation Study design

Screening Donated Blood for Transfusion Transmissible Infections in Bangladesh

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

AccuSet Anti-HIV-1 Mixed Titer Performance Panel

Targeting HIV Settings Through PEPFAR. Bill Coggin, OGAC PEPFAR Laboratory Technical Working Group

Inspections, Compliance, Enforcement, and Criminal Investigations. Central Texas Regional Blood & Tissue Center 07-Nov-03

Minimum Standards for Laboratories in SADC Regions

: New graphic materials for bioelisa and bioblot product lines

A Successful HIV Testing Quality Assurance Program: New York State Experience

Experience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control

HPV Testing What are EQAS and QC data telling us?

Maximizing Cornea and Tissue Donation through Specimen Quality

Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB

Anti-Infective Clinical Trials

Quality Assurance in Immunohaematology for Bhutan, India and Maldives

HIV Testing Technology and the Latest Algorithm

Database on Blood Safety 2009 in ECO Member States

2014/LSIF/PD/008 Building Blocks and Challenges to Implementing a National Blood Program in Malaysia

HUNGARIAN NATIONAL BLOOD TRANSFUSION SERVICE. Dr. Klara Baroti-Tóth, PhD IPFA/PEI 19 th International Workshop Budapest, May, 2012.

FDA Reentry Guidance

Probability of false initial and repeat ID-NAT reactive donations. Marion Vermeulen IPFA Rome 2014

2018 HIV and HCV Diagnostic Testing Survey

Lot Testing of malaria RDTs: achievements and lessons learned from a 7 year-long experience

The application of molecular technology in the HBV/HCV/HIV

Policy for Participation in Proficiency Testing Activities

Traceability in External Quality Assessment: How Weqas ensures traceability in EQA and stresses its importance to users. David Ducroq.

Chapter 5 Serology Testing

Disclosures. Relevant Financial Relationship(s): Nothing to Disclose. Off Label Usage: Nothing to Disclose 9/19/2017. Proficiency Testing

Transcription:

HIV Testing and Systems for Managing HIV Implementation in Resource Limited Settings Elizabeth M. Dax with the staff of the National Serology Reference Laboratory, Australia

My Background Worked in HIV since 1986 when performing clinical studies in NIDA-USA realised that 30% of our subjects were infected. Since 1990: Director: NRL, Australia- Evaluates HIV and other kits pre- and post- market. Set standards & strategies Not a pathologist Involved in international programmes for Laboratory development (WHO, CDC, APHL, ASHM, AIC etc)

Evolution in Titles of the Present Talk HIV Testing and Systems for Managing HIV Implementation in Resource Limited Settings Laboratory Monitoring in the Context of ARV Implementation in Resource-Limited settings Laboratory Monitoring of HIV Infection and Efficacy of ARV Treatment

Assumptions around Titles Unimportant in the present context Of importance is that 95% of HIV infected people do not have adequate access to laboratory screening, diagnostic or monitoring services. Many services are of poor quality Most are not appropriately quality assured

Assumed that:- Clinical Medicine Therapy Good Quality Medical Care Laboratory Support Diagnostics, Monitoring, Blood screening

Successful Testing Systems Suitable policies Effective procurement and distribution Regulation (for tests, laboratories, clinical practice) Laboratory systems (accredited to international standards) Efficient management systems Quality assurance and safety considerations

Involves Government Policy Regulators Laboratory systems Audit & Accreditation system QM & QA

Laboratory Systems NRL(s) Central (Reference) Labs Intermediate Labs Peripheral Labs Health Care Settings

Laboratory Systems - NRL NRL(s) Central (Reference) Labs Intermediate Labs Peripheral Labs Health Care Settings Offers a full range of services Reference testing Quality guidance and programmes Operates high throughput strategies Adjudicates Sets standards Educates

How does NRL assure high quality results? Makes Evaluations sure kits are of of Test high Kits integrity Performance Monitoring Methods: Assures precision QC & accuracy Quality Periodically QAP checks Management processes Monitoring Specificity Batch Checks batch integrity Creates sample Reference testing repositories Testing Assures strategy correct development test usage *Education Training & programmes* networking Delivers reports and programs to generate quality in laboratories

Central Laboratories NRL(s) Central (Reference) Labs Intermediate Labs Peripheral Labs Health Care Settings Offer a range of services (+ confirmatory) + Reference testing Lead in performing quality programmes Operate intermediate throughput strategies Publicly conform to quality standards Educate

Intermediate Laboratories NRL(s) Central (Reference) Labs Intermediate Labs Offer range of tests for basic diagnosis, monitoring Refer samples as necessary Operate to quality assurance and management principles Peripheral Labs Health Care Settings

Peripheral Laboratories NRL(s) Central (Reference) Labs Intermediate Labs Basic services Refer samples Follow quality management and assurance principles Peripheral Labs Health Care Settings

Health Care Centres NRL(s) Central (Reference) Labs Intermediate Labs Peripheral Labs Rapid test diagnosis Refers samples or patients for further testing Basic quality principles followed Health Care Settings

Expectations of Laboratories To produce precise and accurate results To deliver results in a timely manner To attain accreditation to international standards To maintain the health and safety of personnel

Monitoring Infections Maximises:- Good management Treatment efficaciousness Avoiding drug resistance Management of toxicities

NRL s EQAS in SEAWP Regions External Quality Assessment Scheme (EQAS) to SEA-WP - since 1989 EQAS Provider Send samples Analyse results Provide feedback EQAS Participant Test samples Return results Review feedback Improve process In 2003 EQAS for anti-hiv, anti-hcv and HBsAg

NRL s EQAS in SEAWP Regions 15 panels for anti-hiv between 1989 and 2002 78 laboratories 29 countries Collected 13,979 results

Comparative Error Rates Overall error rate for SEA-WP 2.5% 0.8% in Australia Why do laboratories in SEA-WP have more errors than in Australia?

Errors by Laboratory type 6 5 Anti-HIV EQAS Anti-HCV EQAS Errors (%) 4 3 2 1 0 Type of Laboratory

4 3.5 3 2.5 2 1.5 1 0.5 0 Errors by Assay Type Manual IA Agglutination Rapid Immunoblot Total Type of Assay used Anti-HIV EQAS Anti-HCV EQAS Instrument-based IA Errors (%)

Specific Errors Poor sensitivity, specificity of kits No confirmatory testing Sample mix-up Incorrect interpretation Subjective results not checked Carry over Inadequate sample preparation

Errors for anti-hiv and anti-hcv EQAS Anti-HIV EQAS Anti-HCV EQAS Total Test Interpretations 8598 4016 Overall Error Rate* 1.6% 1.4% False Reactives 85.9% 60.7% False Negatives 14.1% 39.3% *Error rate = number of incorrect test interpretations expressed as a ratio of the total interpretations reported.

Errors leading to an incorrect sero-status Anti-HIV EQAS Anti-HCV EQAS % of errors that resulted in an incorrect Sero-status assigned 53% 84% Many errors resolved during subsequent testing Subsequent or confirmatory testing not performed in most laboratories

Performance over time in EQAS Examples from two laboratories Error rate (%) 25 20 15 10 5 Introduced new assay Error rate (%) 25 20 15 10 5 Introduced new assay 0 0 Panel (Year) Panel (Year)

Detection - HIV-1 Group O Percent 120 100 80 60 40 20 0 5000 500 50 TMA Roche copies/ml TMA (Chiron) Roche (HIV-1 Ampliscreen)

ARV Resistance Labs ability to detect nucleotide mixtures Nucleotide Mixtures (%) 100 80 60 40 20 0 1 2 3 4 5 6 7 8 9 10 11 12 Panel 1 Panel 3 Panel 5 Panel 7 Laboratory ID

What is Needed Better government involvement in laboratory Better systems Improved systems Better management and safety Better and more appropriate tests e.g. RT assay for viral load Physician/researcher involvement

New Approaches Referral systems rather than more laboratories Transport systems Better tests for use in resource-limited settings NRL Central (s) Intermediate (Reference) Peripheral Labs Labs Health Care Settings Improved laboratory development mechanisms including QA Insist on donors supporting systems and infrastructure - not individuals

Clinical Medicine Therapy Good Quality Medical Care Laboratory Support Diagnostics, Monitoring, Blood screening